WHAT IS ONCOLYTIC
VIRUS THERAPY?
Engineered viruses that exploit cancer's own broken defences โ selectively destroying tumour cells and triggering systemic immune activation through a two-phase mechanism.
The Two-Phase Mechanism
Normal cells have intact interferon signalling that detects and stops viral replication. Cancer cells have frequently dismantled these same pathways as part of oncogenic transformation โ creating a specific vulnerability that oncolytic viruses exploit.
โCancer's own molecular defects are the targeting system. The virus replicates where the cell can't defend itself.โ
Phase 1: Selective Viral Destruction
The virus enters any cell it can reach. Normal cells contain the infection through intact antiviral defences. Cancer cells with disrupted interferon pathways cannot. The virus replicates, ruptures the cell, releases thousands of viral copies, and the cycle repeats in neighbouring tumour cells.
Phase 2: Immune Activation
When tumour cells rupture, they die immunogenically โ releasing tumour antigens and danger signals. Dendritic cells arrive, T cells get trained against tumour-specific antigens. T cells trained at the injection site circulate and attack cancer cells at distant uninjected sites.
T-VEC: The FDA-Approved Construct
T-VEC (talimogene laherparepvec) is HSV-1 engineered with three modifications: ICP34.5 deletion (prevents replication suppression in normal cells), ICP47 deletion (enhances antigen presentation from infected cells), and GM-CSF insertion (recruits dendritic cells to the tumour site). Administered by direct intratumoral injection into accessible lesions.
Tumour Selectivity
Achieved through deletion of viral genes required for replication in normal but not cancer cells, tumour-specific promoter insertion, or natural tropism for receptors overexpressed on cancer cells. Selectivity is substantial but not absolute.
Cold Tumour Conversion
Oncolytic virus creates immune infiltration where none existed. Checkpoint inhibitors can then release suppression from immune cells that are now present. The virus handles initiation; the checkpoint inhibitor handles suppression.
Delivery Routes
Intratumoral injection is the approved standard. Intravenous delivery to reach visceral metastases is the field's primary unsolved technical problem. Intraperitoneal delivery is in study for peritoneal malignancies.
Who Should Consider Oncolytic Virus Therapy
Patients with unresectable or metastatic melanoma where T-VEC is a current option. Patients with glioblastoma, hepatocellular carcinoma, or head and neck cancers where oncolytic virus trials are open. Anyone told about oncolytic virus therapy who needs the mechanism explained clearly.
Unresectable Melanoma
T-VEC is FDA-approved for unresectable cutaneous, subcutaneous, and nodal melanoma lesions. Stage IIIB-IVM1a patients show the strongest benefit.
Cold Tumour Presentations
When checkpoint inhibitors haven't produced response and cold tumour biology is suspected โ oncolytic virus can convert the microenvironment.
Clinical Trial Candidates
Glioblastoma (PVSRIPO, DNX-2401), liver cancer (vaccinia-based), bladder cancer (CG0070), KRAS-mutant tumours (pelareorep).
Combination Therapy Evaluation
When adding T-VEC to checkpoint inhibitor therapy is being considered for accessible unresectable disease.
Benefits and Limitations
Benefits
- Durable complete responses at 10+ yearsSome OPTiM trial patients maintain complete responses over a decade later.
- No specific mutation requiredSelectivity uses cancer's own broken antiviral machinery โ not a targetable mutation.
- Immune activation at distant sitesDocumented responses at uninjected tumours prove systemic mechanism.
- Manageable safety profileFlu-like symptoms and injection site reactions are the primary toxicities.
Limitations
- Intratumoral injection only for accessible tumoursVisceral metastases cannot be injected with current approved approach.
- Systemic IV delivery remains unsolvedNeutralising antibodies and poor viral persistence in bloodstream limit systemic reach.
- Beyond melanoma, access is trial-dependentMost of the field's clinical potential lives in clinical trials, not approved indications.
When to Consider This Option
When unresectable melanoma is diagnosed or progresses. When a clinical trial listing mentions oncolytic virus and the patient wants to understand the mechanism. When checkpoint inhibitors haven't produced response and cold tumour biology is on the table.
Related Guides & Resources
Explore the complete oncolytic virus therapy framework.
Frequently Asked Questions
About Oncolytic Virus Therapy
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Know If Oncolytic Virus Therapy Is an Option?
Upload your medical reports for a free evaluation. Our team will assess whether T-VEC or an oncolytic virus clinical trial is relevant to your specific diagnosis.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.